Endometrial Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersEndometrial CancerSCE Medical Oncology

A patient with recurrent endometrial cancer has dMMR/MSI-high disease and progression during platinum-based chemotherapy. She has not received a PD-1 inhibitor. Which monotherapy is explicitly recommended by NICE TA779 for this setting?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Dostarlimab

NICE TA779 recommends dostarlimab for advanced or recurrent dMMR/MSI-high endometrial cancer progressing on or after platinum chemotherapy. The distractors target HER2, homologous-recombination deficiency, PIK3CA or tissue factor and do not match the appraisal biomarker and indication.

Reference: NICE TA779: dostarlimab for dMMR or MSI-high endometrial cancer. https://www.nice.org.uk/guidance/ta779/chapter/1-Recommendations